ARTICLES BY THIS AUTHOR
- 8/2/2022
Hy-Vee dietitians hosting healthy back-to-school events in August
Hy-Vee dietitians are hosting a series of programs and workshops focused on helping kids and families prepare for the upcoming school year with healthy recipes. - 8/2/2022
ViiV Healthcare, Medicines Patent Pool provide access to HIV prevention medications
Selected generic manufacturers will have the opportunity to develop, manufacture and supply generic versions of cabotegravir LA for PrEP, the first long-acting HIV prevention medicine, in 90 countries. - 8/2/2022
Marinus launches Ztalmy
Ztalmy is the only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients 2 years of age and older. - 8/2/2022
Amazon adds academic, career coaching to employee benefits
New partnerships with Beyond 12 and Kaplan will provide Amazon employees with career coaching, college advising and specialized career services. - 8/2/2022
CVS Health beats Q2 expectations with increase in prescription volume
Despite facing a challenging economic environment, CVS Health’s Q2 revenues increased to $80.6 billion, up 11% compared with the prior year period. - 8/1/2022
Aurobindo receives FDA OK for generic Letairis
Generic Letairis is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) and also is used in combination with tadalafil. - 8/1/2022
Optum to offer lower-cost Sanofi insulin for uninsured people with diabetes
People living with diabetes who do not have insurance will pay $35 for a 30-day supply of Sanofi insulins. - 8/1/2022
NACDS set to welcome attendees at Total Store Expo 2022
The National Association of Chain Drug Stores is highlighting the upcoming speakers, events and sessions that are on tap at the upcoming TSE in Boston from Aug. 27 to 29. - 8/1/2022
AAM elevates David Gaugh to EVP of sciences, regulatory affairs
Gaugh joined the Association for Accessible Medicines in 2012 as senior vice president of sciences and regulatory affairs. - 8/1/2022
GSK obtains FDA approval for new indication for Benlysta
Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis.